Feng Wang (@fengwan25720657) 's Twitter Profile
Feng Wang

@fengwan25720657

Professor and Director of Medical Oncology dept from Sun Yat-sen University Cancer Center. UT MD Anderson alumni

ID: 1111592948574101504

calendar_today29-03-2019 11:36:26

122 Tweet

216 Followers

262 Following

Feng Wang (@fengwan25720657) 's Twitter Profile Photo

Dr Yuan presented our team's recent phase 2 trial of chemo w/wo toripalimab in the perioperative setting of gastric cancer. #ASCO23 ASCO

Dr Yuan presented our team's recent phase 2 trial of chemo w/wo toripalimab in the perioperative setting of gastric cancer. #ASCO23 <a href="/ASCO/">ASCO</a>
Cell Press (@cellpressnews) 's Twitter Profile Photo

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis - read more from Feng Wang & researchers from Sun Yat-sen University Cancer Center Cell Reports Medicine #ASCO23 hubs.li/Q01RP-rV0

Feng Wang (@fengwan25720657) 's Twitter Profile Photo

Our phase 3 study GLOW was published recently by Nature Medicine. Another standard therapy for advanced gastric cancer patients with positive Claudin18.2. Kohei shitara Saheli Sadanand #asco

Feng Wang (@fengwan25720657) 's Twitter Profile Photo

I am honored to present the results of our investigator initiated phase 2 trial (Capability-01) in the ESMO meeting. A phase 3 is ongoing. #cancer #Immunotherapy

Feng Wang (@fengwan25720657) 's Twitter Profile Photo

I am horned to present the results of AdvanTIG-203, a multi-center international trial of PD-1 with TIGIT antibody as 2nd line for ESCC and enjoyed the section with all excellent speakers. #cancer #Immunotherapy #ESMO23

Feng Wang (@fengwan25720657) 's Twitter Profile Photo

Great experiences in ESMO. Our medical oncology team of Gastrointestinal cancer in Sun Yat-sen University Cancer Center had 6 oral presentations including 2 presented by me. It's always inspiring and exciting to meet the brilliant minds around the world. #ESMO23 #oncology #cancer

Great experiences in ESMO. Our medical oncology team of Gastrointestinal cancer in Sun Yat-sen University Cancer Center had 6 oral presentations including 2 presented by me. It's always inspiring and exciting to meet the brilliant minds around the world. #ESMO23 #oncology #cancer
Shi-Shaun Wong (王诗翔) (@wangshxiang) 's Twitter Profile Photo

Excited to share my recent work published in Nature Communications with the title "Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer." dlvr.it/T2z83z #MachineLearning #CancerGenomics 📚🔬

Feng Wang (@fengwan25720657) 's Twitter Profile Photo

The Capability-01 trial was just published. The combination of HADCi, anti-PD-1 and anti-VEGF achieved an ORR of 44% with a mPFS 7.3 mos in MSS mCRC patients. Thanks to the study team, all patients and family. #colorectalcancer #Immunology #Cancer Nature Medicine

The Capability-01 trial was just published. The combination of HADCi, anti-PD-1 and anti-VEGF achieved an ORR of 44% with a mPFS 7.3 mos in MSS mCRC patients. Thanks to the study team, all patients and family. #colorectalcancer #Immunology #Cancer <a href="/NatureMedicine/">Nature Medicine</a>
Nature Medicine (@naturemedicine) 's Twitter Profile Photo

In a phase 2 trial comparing anti-PD-1 + anti-VEGF + HDAC inhibitor vs. anti-PD-1 + HDAC inhibitor in patients with MSS/pMMR #ColorectalCancer, the triplet combo leads to better 18 week progression-free survival. #ColorectalCancerAwarenessMonth nature.com/articles/s4159…

Feng Wang (@fengwan25720657) 's Twitter Profile Photo

Thanks to Cell for inviting us to write this commentary. Challenges and opportunities in oncology drug development and clinical research in China: Cell cell.com/cell/fulltext/… Cell

Nature Medicine (@naturemedicine) 's Twitter Profile Photo

Now at #ASCO24: In the phase 3 FRUTIGA trial, the multi anti-VEGFR inhibitor #fruquintinib + chemotherapy significantly extended progression-free survival, but not overall survival, as 2L therapy in patients with advanced #GastricCancer or #GEJCancer doi.org/10.1038/s41591…